Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
Palvella Therapeutics reports progress in clinical trials for QTORIN™ rapamycin, exceeding patient enrollment and anticipating significant results in upcoming years. Net loss of $8.2 million for the ...
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is moving toward what could be a defining year, with a late-stage ...
A few years back, Matt Kaeberlein was diagnosed with a frozen shoulder. "It was really bad," he recalls. He wasn't sleeping well and couldn't throw a ball due to the pain. His doctor recommended ...
Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic Malformations and Venous Malformations, among others ...
A few years back, Matt Kaeberlein was diagnosed with a frozen shoulder. "It was really bad," he recalls. He wasn't sleeping well and couldn't throw a ball due to the pain. His doctor recommended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback